Golden Helix and Genomenon Announce Strategic Partnership to Advance Clinical Diagnostics

BOZEMAN, Mont., Sept. 2, 2025 /PRNewswire/ -- Golden Helix, a global leader in clinical bioinformatics, today announced a strategic partnership with Genomenon to integrate its Mastermind Genomic Intelligence Platform and Cancer Knowledgebase (CKB) into the Golden Helix software suite. This collaboration combines two industry-leading platforms to enhance genomic interpretation and deliver high-confidence, literature-backed insights to clinical laboratories worldwide.

Through this integration, Golden Helix customers gain seamless access to Genomenon's expertly curated germline and somatic content directly within VarSeq's annotation engine. These new data layers are fully harmonized alongside trusted public sources like ClinVar, enabling streamlined filtering and prioritized variant interpretation for both inherited diseases and cancer.

"Golden Helix is a recognized leader in clinical genomics, and we're proud to partner with them to deliver Genomenon's rich, evidence-backed insights directly into their analysis workflows," said Mike Klein, CEO of Genomenon. "This integration empowers labs to make faster, more confident clinical decisions by surfacing the most relevant scientific literature and curated genetic data exactly where and when it's needed."

"This partnership allows us to deliver deeply curated literature, pathogenicity insights, and oncology knowledge within the trusted Golden Helix framework our customers rely on every day," said Dr. Andreas Scherer, President and CEO of Golden Helix. "By embedding the rich data and insights from Mastermind and the Cancer Knowledgebase into our platform, we are accelerating the speed and enhancing the accuracy of clinical decision-making — ultimately enabling better outcomes for patients."

Key Benefits of the Partnership
By integrating Genomenon's Mastermind and Cancer Knowledgebase directly into the VarSeq Suite, Golden Helix customers can now access expertly curated genomic content for both inherited disease and cancers alongside their existing workflows. This powerful combination delivers high-confidence insights into variant pathogenicity, biomarker associations, therapeutic relevance, diagnostic criteria, and supporting literature — all within a familiar interpretation environment.

The seamless harmonization of Mastermind and CKB with VarSeq's annotation engine enhances variant prioritization by unifying these premium sources with trusted public databases. This streamlined filtering enables labs to surface the most clinically relevant variants quickly and with greater confidence. As a result, clinical teams can significantly reduce manual curation time, accelerate turnaround, and produce evidence-backed reports with improved consistency and accuracy.

Importantly, this integration is designed for flexibility and scale. Whether deployed on-premises, in the cloud, or within hybrid infrastructures, Golden Helix continues to ensure enterprise-grade data control, security, and regulatory compliance — enabling diagnostic labs worldwide to meet the evolving demands of precision medicine.

To request a demo or learn more, visit www.goldenhelix.com.

About Genomenon

Genomenon is a leading genomic intelligence company transforming patient care by uncovering the genomic drivers of genetic disease and cancer. By combining the power of AI built on the world's premier genomic data set with genomic expertise, the company simplifies complex genetic data into actionable insights. Genomenon's integrated software, data, and services solutions empower clients with advanced patient diagnosis and precision medicine development.

‍Learn more at www.genomenon.com or follow us on LinkedIn.

About Golden Helix

Golden Helix has delivered trusted bioinformatics solutions for over 25 years to hospitals, testing labs, research institutions, and national genome programs around the world. With powerful tools for tertiary analysis and genomic warehousing, Golden Helix empowers customers to uncover disease-causing mutations, personalize treatment decisions, and accelerate discoveries in rare diseases and oncology.

Casey Fullem
Director of Marketing
Golden Helix, Inc.
(406) 551-4901
[email protected]

View original content to download multimedia:https://www.prnewswire.com/news-releases/golden-helix-and-genomenon-announce-strategic-partnership-to-advance-clinical-diagnostics-302542158.html

SOURCE Golden Helix Inc